header logo image


Page 277«..1020..276277278279..290300..»

Does Organic Mean Non-GMO? Here’s the Difference Between the Two – Green Matters

January 12th, 2021 3:55 am

Furthermore, there's somewhat of a gray area when it comes to understanding what organic means, and its relationship to genetically modified organisms (GMOs). Does an organic label automatically mean the item is non-GMO? Is organic always considered non-GMO? And what does non-GMO mean anyway? Keep reading to learn more about organic standards and non-GMO.

An organic label refers to an organism (plant, crop, food, or fabric) that has been produced without the aid of chemical or synthetic fertilizers, pesticides, herbicides, insecticides, or fungicides. In order to reach the certification standard of organic, items cannot be grown using antibiotics or artificial growth hormones either. If items have used fertilizers, pesticides, artificial growth hormones, or antibiotics during the growing process, these items are referred to as conventional.

Is organic better? There are absolutely environmental and health benefits to buying organic. According to Organic Trade Association, such benefits include promoting public health and health of the environment, no use of toxic pesticides and petroleum-based fertilizers, increased levels of nutrients and antioxidants, no use of artificial preservatives, colorings, added flavors, or ionizing radiation, and no antibiotics, growth hormones, or artificial drugs.

Article continues below advertisement

Organic regulations also constitute specific regulations about soil, ensuring the soil in which organic seeds are grown is healthy and promotes biodiversity, which is another meaningful environmental benefit.

Article continues below advertisement

In order to live up to the stringent organic standards, an item may not be genetically modified. According to USDA, the use of GMOs in organic products is explicitly prohibited in the definition of what organic is. The USDA states, The use of genetic engineering, or genetically modified organisms (GMOs), is prohibited in organic products. This means an organic farmer cant plant GMO seeds, an organic cow cant eat GMO alfalfa or corn, and an organic soup produced cant use any GMO ingredients.

You may be wondering, though: What guarantee is there that farmers wont use GMOs in their alleged organic products? Well, the USDA makes it difficult for farmers to get an organic certification. First, farmers have to prove that they can meet USDA organic standards. The website continues, To meet the USDA organic regulations, farmers and processors must show they arent using GMOs and that they are protecting their products from contact with prohibited substances, such as GMOs, from farm to table.

Article continues below advertisement

The USDA also has a National List of Allowed and Prohibited Substances for organic products and GMOs arent the only items on the list. The list also prohibits ash from manure burning, arsenic, calcium chloride, lead salts, potassium chloride, rotenone, sodium fluoaluminate, sodium nitrate, strychnine, and tobacco dust.

Article continues below advertisement

Yes, according to the USDAs very vigorous standards, all foods labeled organic are inherently also non-GMO. This means organic foods have not been genetically modified in anyway. In the example of organic meat, this means an organic cow was not fed any feed that was genetically modified either.

That being said, certain foods are at a higher risk for being genetically engineered or modified in some way, so if youre looking to only eat non-GMO, you might want to only eat these foods if they specifically are labeled organic or non-GMO. According to CNN, vegetables that are high-risk for GMOs include edamame, sweet corn, yellow summer squash, zucchini, and papaya from Hawaii or China. So, make sure to buy those organic.

Article continues below advertisement

Prganic seeds are also non-GMO. An organic farmer is not allowed, under the USDAs standards, to plant genetically modified seeds. According to a 2014 article from the USDAs blog, organic seeds are described as a fundamental right from the start.

The article states, The use of organic seed is also an important aspect of organic certification. During each farms annual review and inspection, certifying agents also verify that certified operations use organic seed varieties."

Article continues below advertisement

Certifying agents also make sure that USDA organic products meet all of the organic standards, including reviewing substances and inputs used to treat seeds and planting stock.

The article also adds, Like other organic products, seeds used in organic agriculture cannot be genetically engineered or be treated with prohibited substances.

Article continues below advertisement

To ensure that organic seeds get proper treatment on organic farms, the USDA works with the National Organic Program (NOP), the Organic Seed Alliance (OSA), and the Association of Official Seed Certifying Agencies (AOSCA). These organizations collaborate to better understand the organic seed market and to help farmers locate seed producers and supplies. This is a direct response to an increased demand for organic seeds, as the demand for organic food increases.

To help with this increase in demand, the NOP aided the USDA in the creation of the AOSCA Organic Seed Finder, a website that works to connect organic seed vendors with potential customers. The website allows users to search specific categories such as vegetables, fruits, herbs and flowers, and field crops, to accurately curate searches based on what the user is looking for.

The USDA states, Certifying agents and organic operations can use this tool to locate available organic seed and ensure the integrity of those seeds.

Read more here:
Does Organic Mean Non-GMO? Here's the Difference Between the Two - Green Matters

Read More...

UPDATED: Bluebird spins itself into two companies, severing gene therapy and cancer units – Endpoints News

January 12th, 2021 3:55 am

Bluebird bio, once one of biotechs flashiest companies, is taking a sweeping step as it looks to right the ship after a series of high-profile setbacks: splitting the company in two.

The Cambridge-based company will split itself into a unit focused on cancer and a unit focused on rare disease, severing the cell therapy and gene therapy units that the biotech rode to prominence. CEO Nick Leschly explained the move as a practical one, reflecting the different kinds of expertise in the disease areas.

You dont build an oncology company by hiring people who are experts in severe genetic disease, nor do you do vice versa, Leschly told WSJ. A lot of this comes down to priorities and focus.

Yet the move comes as bluebirds stock has lost much of its initial luster, as bluebird has struggled to turn strong data into commercial therapies and investors moved on to newer gene therapy companies such as CRISPR Therapeutics.

And it will effectively end Leschlys day-to-day involvement in the biotech he has become synonymous with and a gene therapy field where he long served as the most prominent CEO. Leschly will lead the as-yet-unnamed newco, while Andrew Obenshain, their longtime European chief, will lead bluebird bio. Leschly will hang on as bluebirds executive chair.

Analysts were skeptical that the approach was the solution. In a note to investors, Piper Sandlers Tyler Van Buren said bluebird had struggled to replenish its pipeline over the years, despite significant funding, and he worried that they didnt have enough assets or cash to sustain multiple companies.

Ultimately, while these two franchises are different, we are not convinced that their respective pipelines are robust enough to sustain the independent entities, he wrote, and we believe some investors appreciated the balance of the two franchises.

The companys stock $BLUE, which has fallen dramatically from its 2011 peak, when it was worth over $11 billion, remained flat at just under $49.

After commanding attention with curative data for a sickle cell gene therapy and numerous remissions in trials for a multiple myeloma cell therapy, bluebird has struggled to bring both past the finish line.

After their most recent delay, the company remains nearly two years away from submitting their sickle cell gene therapy to the FDA. The FDA is now reviewing the multiple myeloma cell therapy ide-cel, now partnered with Bristol Myers Squibb, but the agency initially served the company with a refuse-to-file letter for submitting insufficient manufacturing information.

The gene therapy, known as Zynteglo, was approved in Europe for another rare blood disease, beta thalassemia. But the $1.8 million price tag bluebird placed on it shocked analysts and industry watchers and, with the pandemic hitting shortly after their official launch, the company had yet to sell a single unit as of their November Q3 filing.

Despite the setbacks, the company still remains at the front of a now crowded pack to commercialize a sickle cell cure, and analysts peg peak sales for ide-cel as high as $900 million. Bluebird also has an immunotherapy for Merkel cell carcinoma and a gene therapy for cerebral adrenoleukodystrophy in clinical development.

Read the rest here:
UPDATED: Bluebird spins itself into two companies, severing gene therapy and cancer units - Endpoints News

Read More...

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 12th, 2021 3:53 am

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, has entered into an employment agreement with a newly hired employee that, among other things, provides for the grant of a non-qualified stock option and of restricted stock units as inducements material to the employee entering into employment with Voyager. The inducement awards were approved by the Compensation Committee of Voyager’s Board of Directors in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option award became effective on January 11, 2021 and the restricted stock unit award becomes effective on February 1, 2021.

Here is the original post:
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Read More...

GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020

January 12th, 2021 3:53 am

CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020.

Read more:
GenMark Diagnostics Provides Preliminary Operational and Financial Results for 2020

Read More...

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

January 12th, 2021 3:53 am

Lille, France; Cambridge, MA; January 11, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Follow this link:
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

Read More...

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

January 12th, 2021 3:53 am

Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. In pre-clinical studies, binding to Fc?R on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

Continue reading here:
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Read More...

INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

January 12th, 2021 3:53 am

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021.

Here is the original post:
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

Read More...

Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

January 12th, 2021 3:53 am

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Officer, Dr Silviu Itescu, today presented additional data from the landmark DREAM-HF Phase 3 trial in patients with chronic heart failure. The presentation materials have been lodged with the ASX, and Mesoblast’s presentation at the H.C. Wainwright Virtual BioConnect 2021 Conference can be accessed at https://journey.ct.events/view/f353f7fd-772e-43aa-aab0-e959da38254d. An archived webcast of the conference presentation will be available for 90 days on the Company’s website at www.mesoblast.com.

Link:
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference

Read More...

Generation Bio Announces Closing of Public Offering

January 12th, 2021 3:53 am

Continue reading here:
Generation Bio Announces Closing of Public Offering

Read More...

IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

January 12th, 2021 3:53 am

- IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors - - IGM to Develop Birinapant in Combination with IGM-8444 for the Treatment of Solid Tumors -

Here is the original post:
IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Read More...

T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

January 12th, 2021 3:53 am

Panel can detect multiple variants of the SARS-CoV-2 virus, including those most recently identified in the United Kingdom, South Africa, and the U.S.

Read more:
T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus

Read More...

Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

January 12th, 2021 3:53 am

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Read the original here:
Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units

Read More...

Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

January 12th, 2021 3:53 am

Jiuquan, China, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”), a China-based pharmaceutical and chemical products manufacturer, today announced the pricing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share. The ordinary shares have been approved for listing on the Nasdaq Global Market and are expected to commence trading on January 12, 2021 under the ticker symbol “QLI”.

Read the original post:
Qilian International Holding Group Limited Announces Pricing of Initial Public Offering

Read More...

Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

January 12th, 2021 3:53 am

- Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma

Go here to see the original:
Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health

Read More...

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common…

January 12th, 2021 3:53 am

Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

View post:
Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common...

Read More...

Addex to Present at the Baader Helvea Swiss Equities Conference

January 12th, 2021 3:53 am

Geneva, Switzerland, January 12, 2021 -  Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 – January 15, 2021.

Read the original post:
Addex to Present at the Baader Helvea Swiss Equities Conference

Read More...

Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

January 12th, 2021 3:53 am

REGULATED INFORMATION

Go here to see the original:
Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

Read More...

iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

January 12th, 2021 3:53 am

PRESS RELEASE

See the original post:
iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19  

Read More...

BetterLife Provides Shareholder Update and 2021 Product Development Roadmap

January 12th, 2021 3:53 am

VANCOUVER, Jan. 11, 2021 (GLOBE NEWSWIRE) -- VANCOUVER, January 12, 2021 - BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, is pleased to provide an overview of the Company’s primary plans for this calendar year to develop 3 novel therapeutic products, each addressing significant unmet needs with multi-billion dollar market potential.

See the article here:
BetterLife Provides Shareholder Update and 2021 Product Development Roadmap

Read More...

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

January 12th, 2021 3:53 am

SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.

See more here:
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19

Read More...

Page 277«..1020..276277278279..290300..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick